Safety of intravenously applied mistletoe extract - results from a phase I dose escalation study in patients with advanced cancer.

PubWeight™: 0.75‹?›

🔗 View Article (PMID 28923036)

Published in BMC Complement Altern Med on September 18, 2017

Authors

Roman Huber1, Dietrich Schlodder2, Carola Effertz2, Sabine Rieger2, Wilfried Tröger3

Author Affiliations

1: Center for Complementary Medicine, University Medical Center Freiburg, Faculty of Medicine, University of Freiburg, Breisacher Str. 115B, 79106, Freiburg im Breisgau, Germany. roman.huber@uniklinik-freiburg.de.
2: Helixor Heilmittel GmbH, Rosenfeld, Germany.
3: Clinical Research Dr. Tröger, Freiburg, Germany.

Articles cited by this

Design and analysis of phase I clinical trials. Biometrics (1989) 4.31

Mistletoe therapy in oncology. Cochrane Database Syst Rev (2008) 1.84

Induction of maturation and activation of human dendritic cells: a mechanism underlying the beneficial effect of Viscum album as complimentary therapy in cancer. BMC Cancer (2008) 0.97

Abnormality on liver function test. Pediatr Gastroenterol Hepatol Nutr (2013) 0.94

Pharmacokinetics of natural mistletoe lectins after subcutaneous injection. Eur J Clin Pharmacol (2010) 0.90

Mistletoe treatment induces GM-CSF- and IL-5 production by PBMC and increases blood granulocyte- and eosinophil counts: a placebo controlled randomized study in healthy subjects. Eur J Med Res (2005) 0.90

Mistletoe extract reduces the surgical suppression of natural killer cell activity in cancer patients. a randomized phase III trial. Forsch Komplementmed (2007) 0.90

Cytotoxic activity and absence of tumor growth stimulation of standardized mistletoe extracts in human tumor models in vitro. Anticancer Res (2007) 0.90

The influence of isorel on the advanced colorectal cancer. Cancer Biother Radiopharm (2003) 0.88

Safety and effects of two mistletoe preparations on production of Interleukin-6 and other immune parameters - a placebo controlled clinical trial in healthy subjects. BMC Complement Altern Med (2011) 0.88

Phase I trial of r viscumin (INN: aviscumine) given subcutaneously in patients with advanced cancer: a study of the European Organisation for Research and Treatment of Cancer (EORTC protocol number 13001). Eur J Cancer (2008) 0.84

Safety of Intravenous Application of Mistletoe (Viscum album L.) Preparations in Oncology: An Observational Study. Evid Based Complement Alternat Med (2014) 0.83

Mistletoe lectin transport by M-cells in follicle-associated epithelium (FAE) and IL-12 secretion in dendritic cells situated below FAE in vitro. Arch Pharm Res (2010) 0.82

[The effect of mistletoe lectins on the limulus amebocyte lysate test]. Arzneimittelforschung (1993) 0.79